← All trials
NCT04705727
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 12, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Jul 31, 2022
- First posted
- Jan 12, 2021
- Last posted
- Sep 8, 2021
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Centre Hospitalier Intercommunal CreteilLead sponsor
- AstraZenecaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.